SCHEMBL8175155

SCHEMBL8175155

CC(C)c1ccc(Cn2c(C(N)=O)c(CC(=O)O)c3ccccc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 5/20 0.53
THRB P10828 5/20 0.53
FOLH1 Q04609 3/20 0.52
PTGDR2 Q9Y5Y4 1/20 0.51
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GFER P55789 1/20 0.47
PLA2G2A P14555 1/20 0.46
PTPN1 P18031 1/20 0.45
CCR2 P41597 3/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
EGFR P00533 1/20 0.43
PTGES O14684 1/20 0.42
ALOX5 P09917 1/20 0.42
YWHAH Q04917 1/20 0.41
PTGES2 Q9H7Z7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4266132 0.91 FOLH1 (0.63) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL13952634 0.88 FOLH1 (0.44) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL8167551 0.86 THRA (0.54) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL8171635 0.85 MEN1 (0.53) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL4270126 0.85 THRA (0.71) THRATHRBPTGDR2MEN1KMT2A
SCHEMBL8175100 0.84 THRA (0.48) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL8167328 0.83 MEN1 (0.52) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL8165192 0.82 MEN1 (0.53) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL8179717 0.81 PTGER4 (0.49) THRATHRBFOLH1PTGDR2MEN1
SCHEMBL8180136 0.81 THRA (0.52) THRATHRBFOLH1PTGDR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS THRA 4588/4885THRB 4376/4885FOLH1 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.